(Q36872038)

16 August 2017

1 reference

title

Inhibitor development in haemophilia B: an orphan disease in need of attention (English)

1 reference

16 August 2017

0 references

0 references

1 reference

1 reference

Donna DiMichele

1

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

British Journal of Haematology

16 August 2017

published in

1 reference

16 August 2017

volume

138

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

305-315

1 reference

Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Central venous catheter‐related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Rituximab for adolescents with haemophilia and high titre inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Tolerance induction using the Malmö treatment model 1982-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Identification of T-cell epitopes in clotting factor IX and lack of tolerance in inbred mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Inhibitors in congenital coagulation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Prophylaxis in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

The evidence behind inhibitor treatment with recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Basic aspects of bypassing agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Genetic risk factors for inhibitors to factors VIII and IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

The promise and challenges of bioengineered recombinant clotting factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

21 January 2018

FEIBA: mode of action

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Factor IX inhibitors and anaphylaxis in hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06657.X

10.1111/J.1365-2141.2007.06657.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference